Traws Pharma, Inc.

TRAW

$0.54

-4.91%

N/A-$0.03

Healthcare

Biotechnology

NASDAQ

Active Trading

Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat ...

Supply Chain of TRAW

Upstream

Foundry, packaging, memory, wafers, components, and input vendors.

Upstream

Viriom, Inc.

Temple University

Expert Systems Inc.

Unnamed CDMOs (Contract Development & Manufacturing Organizations)

HanX Biopharmaceuticals (Wuhan) Co., Ltd.

Viriom, Inc.

IP licensor and asset seller - provided foundational antiviral patents/compounds for tivoxavir marboxil and ratutrelvir via license agreement (later asset purchase in Sep 2025 for $2.35M)

Temple University

Exclusive worldwide IP licensor since 1999 covering foundational oncology compounds (rigosertib platform)

Expert Systems Inc.

Life sciences accelerator / CRO partner supporting Phase 2 clinical studies of ratutrelvir (TRX01); AI/ML-enabled drug development services

Unnamed CDMOs (Contract Development & Manufacturing Organizations)

API and drug product manufacturing for clinical trial supplies of tivoxavir marboxil and ratutrelvir; Traws relies on third-party manufacturers under individual purchase orders

HanX Biopharmaceuticals (Wuhan) Co., Ltd.

HKEx:3378

License and collaboration partner for Greater China rights to rigosertib and narazaciclib (oncology assets); also a downstream licensee

Downstream

Customers, distributors, OEMs, and channels that absorb output.

Downstream

Knight Therapeutics Inc.

Specialised Therapeutics Asia Pte Ltd.

Pint Pharma International SA (Pint International SA)

SymBio Pharmaceuticals Limited

Knight Therapeutics Inc.

TSX:GUD

Licensee for commercialization rights in Canada and select international territories for legacy oncology products under Knight License Agreement

Specialised Therapeutics Asia Pte Ltd.

Distribution, license and supply partner for Australia, New Zealand and Southeast Asia under STA License Agreement (Dec 2019)

Pint Pharma International SA (Pint International SA)

License, development and commercialization partner for Latin America under Pint License Agreement (Mar 2018)

SymBio Pharmaceuticals Limited

TYO:4582

Former licensee for rigosertib in Japan and Korea (license mutually terminated April 2025); historical downstream partner only

Proxies

Public comparables and monitoring names used as representatives for the analysis.

Proxies

Knight Therapeutics Inc.

HanX Biopharmaceuticals (Wuhan) Co., Ltd.

SymBio Pharmaceuticals Limited

Roche Holding AG

Knight Therapeutics Inc.

TSX:GUD

Traws Pharma's key downstream licensing partner in Canada; provides commercial-stage revenue exposure as a specialty pharma proxy for Traws' potential future commercialization

HanX Biopharmaceuticals (Wuhan) Co., Ltd.

HKEx:3378

Licensing partner for Greater China rights to Traws' oncology assets; publicly listed in December 2025 on HKEX, offering visibility into the value of Traws' licensed pipeline in China

SymBio Pharmaceuticals Limited

TYO:4582

Former licensee (terminated) provides historical reference for how Traws' assets were valued; publicly traded on Tokyo Stock Exchange

Pfizer Inc.

NYSE:PFE

Competitive proxy: PAXLOVID (nirmatrelvir/ritonavir) is the dominant COVID-19 antiviral that ratutrelvir aims to compete with/improve upon

Roche Holding AG

SWX:ROG

Competitive proxy: Tamiflu (oseltamivir) and Xofluza (baloxavir marboxil, partnered with Shionogi) are the dominant influenza antivirals that tivoxavir marboxil aims to compete with

Geographic

Region-level exposures that can distort the supply network.

Geographic

United States (Pennsylvania)

Canada

China (Greater China)

Traws Pharma, Inc.

Knight Therapeutics Inc.

HanX Biopharmaceuticals (Wuhan) Co., Ltd.

United States (Pennsylvania)

Single HQ and operational hub; all management, R&D oversight, and regulatory strategy centralized in Newtown, PA

Traws Pharma, Inc.NASDAQ:TRAWCorporate headquarters with all key operations

Canada

Downstream commercialization dependency via Knight Therapeutics for Canadian market licensing

Knight Therapeutics Inc.TSX:GUDLicensee for Canadian commercialization rights

China (Greater China)

License dependency on HanX Biopharmaceuticals for oncology asset development in Greater China; now a Hong Kong-listed entity

HanX Biopharmaceuticals (Wuhan) Co., Ltd.HKEX:3378License and collaboration partner for Greater China (rigosertib, narazaciclib)

Latin America

Downstream commercialization dependency via Pint Pharma International SA for Latin American markets

Pint Pharma International SALicense, development and commercialization partner for Latin America

Asia-Pacific (Australia/NZ/SE Asia)

Downstream distribution dependency via Specialised Therapeutics Asia for APAC markets

Specialised Therapeutics Asia Pte Ltd.Distribution, license and supply partner for APAC

Concentration

Customer, supplier, or partner concentration exposures that can distort the supply network.

Customer

Critical

Zero commercial revenue concentration risk is mitigated only by future dependence on a small number of licensing/distribution partners (Knight, STA, Pint) for any future product sales; all pipeline assets are pre-commercial

Foundry

Medium

Not applicable (biopharmaceutical company, not semiconductor); however, reliance on undisclosed CDMOs for clinical trial material creates single/limited-source supplier risk for API and drug product

Equipment

Medium

Dependence on specialized CRO and CDMO service providers for clinical trial execution and manufacturing; no in-house manufacturing capabilities

Other

High

IP concentration risk: Key antiviral platform depends on Viriom-originated patents (asset purchase); oncology platform depends on Temple University license. Loss of either would be existential.

Revenue mix

How the target's revenue mix translates into supply-chain leverage and dependency.

License & Collaboration Revenue (Oncology Legacy)

0.0%

$0.0B

Pre-commercial; minimal revenue from terminated SymBio license deferred revenue recognition in 2025. No commercial supply chain yet.

Antiviral Pipeline (Tivoxavir Marboxil / Ratutrelvir)

0.0%

$0.0B

All pipeline assets are investigational with no approved products. Supply chain consists of clinical-stage CRO/CDMO services and API procurement for trials.

Oncology Pipeline (Rigosertib / Narazaciclib)

0.0%

$0.0B

Legacy assets from Onconova; seeking licensing partners. No commercial manufacturing active.

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Traws Pharma, Inc.

Supply Chain of TRAW

Upstream

Viriom, Inc.

Temple University

Expert Systems Inc.

Unnamed CDMOs (Contract Development & Manufacturing Organizations)

HanX Biopharmaceuticals (Wuhan) Co., Ltd.

Downstream

Knight Therapeutics Inc.

Specialised Therapeutics Asia Pte Ltd.

Pint Pharma International SA (Pint International SA)

SymBio Pharmaceuticals Limited

Proxies

Knight Therapeutics Inc.

HanX Biopharmaceuticals (Wuhan) Co., Ltd.

SymBio Pharmaceuticals Limited

Pfizer Inc.

Roche Holding AG

Geographic

United States (Pennsylvania)

Canada

China (Greater China)

View More

Supply Chain of TRAW

Upstream

Viriom, Inc.

Temple University

Expert Systems Inc.

Unnamed CDMOs (Contract Development & Manufacturing Organizations)

HanX Biopharmaceuticals (Wuhan) Co., Ltd.

Downstream

Knight Therapeutics Inc.

Specialised Therapeutics Asia Pte Ltd.

Pint Pharma International SA (Pint International SA)

SymBio Pharmaceuticals Limited

Proxies

Knight Therapeutics Inc.

HanX Biopharmaceuticals (Wuhan) Co., Ltd.

SymBio Pharmaceuticals Limited

Pfizer Inc.

Roche Holding AG

Geographic

United States (Pennsylvania)

Canada

China (Greater China)

View More